Share Price and Basic Stock Data
Last Updated: January 14, 2026, 10:35 pm
| PEG Ratio | -2.96 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Archit Organosys Ltd operates in the chemicals sector, specifically focusing on organic chemicals. The company’s market capitalization stood at ₹85.0 Cr, with a share price of ₹41.4. Revenue trends indicate fluctuations, with sales reported at ₹138 Cr for FY 2022 and declining to ₹128 Cr in FY 2023, before a rebound to ₹126 Cr in FY 2025. Quarterly sales figures also reveal variability; for instance, sales peaked at ₹46.55 Cr in March 2023 but dropped to ₹22.42 Cr in December 2022. The most recent quarter, September 2023, reported sales of ₹26.39 Cr. Despite these fluctuations, Archit Organosys recorded a trailing twelve-month sales figure of ₹135 Cr, indicating a potential recovery trend. The company’s operational performance is further reflected in its operating profit margin (OPM), which fluctuated significantly, reaching a low of 4.43% in December 2023 before recovering to 8.22% in September 2025. This inconsistency in revenue and profit margins underscores the challenges faced by the company in maintaining stable growth.
Profitability and Efficiency Metrics
The profitability metrics for Archit Organosys highlight a mixed performance over recent quarters. The reported net profit for FY 2023 was ₹11 Cr, which declined to ₹3 Cr in FY 2024, before rising again to ₹5 Cr in FY 2025. The earnings per share (EPS) reflected this volatility, with figures of ₹5.57 in FY 2023 and ₹2.46 in FY 2025. Operating profit margins also showed significant variation, with a high of 15% in FY 2023, but declining to 6% in FY 2024, and recovering to 10% in FY 2025. Additionally, the interest coverage ratio stood at a strong 6.23x, indicating that the company is managing its interest obligations effectively. However, the return on equity (ROE) reported at 7.62% remains below the sector average, suggesting room for improvement in profitability relative to shareholder equity. The cash conversion cycle of -8 days reflects excellent efficiency in managing working capital, positioning Archit Organosys favorably compared to industry norms.
Balance Sheet Strength and Financial Ratios
Archit Organosys exhibits a solid balance sheet, with total assets reported at ₹123 Cr and total liabilities at ₹108 Cr for FY 2025, resulting in a debt-to-equity ratio of 0.38. This indicates a conservative approach to leveraging, particularly as long-term debt stands at ₹0.06, highlighting minimal reliance on debt financing. The company’s reserves have steadily increased, reaching ₹52 Cr by September 2025, which enhances its financial stability. The price-to-book value (P/BV) ratio of 1.11x suggests the stock is fairly valued compared to its book value. Furthermore, the current ratio of 1.35 indicates adequate short-term liquidity to meet obligations. However, the company’s return on capital employed (ROCE) at 11% is lower than the typical sector range, pointing to inefficiencies in utilizing capital for generating returns. The earnings yield of 6% further emphasizes the need for improved profitability to attract investor interest.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Archit Organosys indicates a strong promoter holding of 65.39%, with public shareholders holding 34.60%. This concentration of ownership suggests a stable governance structure, as the promoters have consistently increased their stake over recent quarters, from 61.64% in December 2022 to the current level. The number of shareholders also reflects growing interest, standing at 9,847 as of September 2025, up from 9,608 in December 2022. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) may signal a lack of confidence or interest from larger institutional players. This could potentially affect stock liquidity and market perception. The dividend payout, which was zero for FY 2024 and FY 2025, may further impact investor sentiment, as consistent dividends are often seen as a sign of financial health and shareholder return. Overall, while promoter confidence appears strong, the lack of institutional backing presents a risk to broader investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Archit Organosys faces both opportunities and challenges. The company’s ability to stabilize and grow its revenue is critical, particularly after recent fluctuations in sales and profitability. Strengths include a strong promoter backing, efficient working capital management, and a solid balance sheet with low debt levels. However, risks include the company’s inconsistent earnings performance, reliance on a concentrated shareholder base, and the absence of institutional investments, which could affect market confidence. Additionally, external factors such as commodity price volatility and regulatory changes in the chemicals sector may pose risks to future performance. To enhance investor confidence and improve financial metrics, Archit Organosys may need to focus on operational efficiencies and possibly re-evaluate its dividend policy to attract a broader investor base. Overall, while the company shows potential for recovery, it must address these challenges to solidify its market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 73.2 Cr. | 205 | 456/192 | 170 | 392 | 0.05 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,083 Cr. | 8,935 | 14,250/8,150 | 51.3 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 30.1 Cr. | 100 | 329/93.4 | 14.9 | 26.9 | 1.00 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 224 Cr. | 280 | 435/163 | 12.4 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,547.08 Cr | 1,466.67 | 59.95 | 334.84 | 0.41% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.46 | 22.42 | 46.55 | 31.00 | 26.39 | 24.81 | 30.99 | 27.00 | 29.54 | 25.87 | 43.18 | 33.20 | 32.86 |
| Expenses | 23.23 | 18.83 | 43.63 | 27.76 | 24.28 | 23.71 | 30.70 | 23.95 | 26.69 | 23.21 | 38.76 | 29.06 | 30.16 |
| Operating Profit | 5.23 | 3.59 | 2.92 | 3.24 | 2.11 | 1.10 | 0.29 | 3.05 | 2.85 | 2.66 | 4.42 | 4.14 | 2.70 |
| OPM % | 18.38% | 16.01% | 6.27% | 10.45% | 8.00% | 4.43% | 0.94% | 11.30% | 9.65% | 10.28% | 10.24% | 12.47% | 8.22% |
| Other Income | 0.17 | 1.84 | 1.35 | 0.71 | 0.54 | 0.52 | 4.11 | 0.47 | 0.63 | 0.93 | 1.06 | 1.00 | 1.46 |
| Interest | 0.32 | 0.52 | 0.50 | 0.52 | 0.65 | 0.77 | 0.64 | 0.62 | 0.78 | 0.47 | 0.71 | 0.60 | 0.67 |
| Depreciation | 1.17 | 1.31 | 1.17 | 1.19 | 1.49 | 1.49 | 1.48 | 1.49 | 1.50 | 1.49 | 1.46 | 1.49 | 1.52 |
| Profit before tax | 3.91 | 3.60 | 2.60 | 2.24 | 0.51 | -0.64 | 2.28 | 1.41 | 1.20 | 1.63 | 3.31 | 3.05 | 1.97 |
| Tax % | 21.74% | 37.78% | 22.69% | 26.79% | 27.45% | -29.69% | 21.49% | 29.08% | 15.00% | 37.42% | 38.67% | 33.11% | 21.83% |
| Net Profit | 3.06 | 2.24 | 2.01 | 1.64 | 0.37 | -0.46 | 1.79 | 1.01 | 1.02 | 1.01 | 2.02 | 2.04 | 1.54 |
| EPS in Rs | 1.49 | 1.09 | 0.98 | 0.80 | 0.18 | -0.22 | 0.87 | 0.49 | 0.50 | 0.49 | 0.98 | 0.99 | 0.75 |
Last Updated: December 28, 2025, 3:02 am
Below is a detailed analysis of the quarterly data for Archit Organosys Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 32.86 Cr.. The value appears to be declining and may need further review. It has decreased from 33.20 Cr. (Jun 2025) to 32.86 Cr., marking a decrease of 0.34 Cr..
- For Expenses, as of Sep 2025, the value is 30.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.06 Cr. (Jun 2025) to 30.16 Cr., marking an increase of 1.10 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.70 Cr.. The value appears to be declining and may need further review. It has decreased from 4.14 Cr. (Jun 2025) to 2.70 Cr., marking a decrease of 1.44 Cr..
- For OPM %, as of Sep 2025, the value is 8.22%. The value appears to be declining and may need further review. It has decreased from 12.47% (Jun 2025) to 8.22%, marking a decrease of 4.25%.
- For Other Income, as of Sep 2025, the value is 1.46 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 1.46 Cr., marking an increase of 0.46 Cr..
- For Interest, as of Sep 2025, the value is 0.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.60 Cr. (Jun 2025) to 0.67 Cr., marking an increase of 0.07 Cr..
- For Depreciation, as of Sep 2025, the value is 1.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.49 Cr. (Jun 2025) to 1.52 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.97 Cr.. The value appears to be declining and may need further review. It has decreased from 3.05 Cr. (Jun 2025) to 1.97 Cr., marking a decrease of 1.08 Cr..
- For Tax %, as of Sep 2025, the value is 21.83%. The value appears to be improving (decreasing) as expected. It has decreased from 33.11% (Jun 2025) to 21.83%, marking a decrease of 11.28%.
- For Net Profit, as of Sep 2025, the value is 1.54 Cr.. The value appears to be declining and may need further review. It has decreased from 2.04 Cr. (Jun 2025) to 1.54 Cr., marking a decrease of 0.50 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.75. The value appears to be declining and may need further review. It has decreased from 0.99 (Jun 2025) to 0.75, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:12 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 56 | 51 | 48 | 82 | 84 | 77 | 95 | 138 | 128 | 113 | 126 | 135 |
| Expenses | 47 | 53 | 48 | 44 | 78 | 87 | 73 | 83 | 121 | 108 | 106 | 113 | 121 |
| Operating Profit | 2 | 2 | 3 | 4 | 4 | -3 | 4 | 11 | 17 | 20 | 7 | 13 | 14 |
| OPM % | 5% | 4% | 6% | 8% | 5% | -4% | 5% | 12% | 12% | 15% | 6% | 10% | 10% |
| Other Income | -0 | 1 | 1 | 0 | 3 | 3 | 2 | 0 | 1 | 3 | 6 | 3 | 4 |
| Interest | 1 | 1 | 1 | 1 | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 6 |
| Profit before tax | 1 | 1 | 2 | 3 | 0 | -6 | -1 | 5 | 11 | 15 | 4 | 8 | 10 |
| Tax % | 33% | 43% | 37% | 42% | -32% | -25% | 1% | -7% | 28% | 26% | 24% | 33% | |
| Net Profit | 1 | 1 | 1 | 2 | 1 | -5 | -1 | 5 | 8 | 11 | 3 | 5 | 7 |
| EPS in Rs | 0.65 | 0.87 | 0.97 | 1.14 | 0.34 | -3.14 | -0.53 | 3.34 | 4.01 | 5.57 | 1.63 | 2.46 | 3.21 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 15% | 19% | 9% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 100.00% | -50.00% | -600.00% | 80.00% | 600.00% | 60.00% | 37.50% | -72.73% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 100.00% | -150.00% | -550.00% | 680.00% | 520.00% | -540.00% | -22.50% | -110.23% | 139.39% |
Archit Organosys Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | -3% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 51% |
| 3 Years: | -16% |
| TTM: | 8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 34% |
| 3 Years: | -13% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 8% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 2:21 pm
Balance Sheet
Last Updated: December 4, 2025, 2:24 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 5 | 10 | 15 | 15 | 15 | 15 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 2 | 2 | 8 | 17 | 25 | 20 | 19 | 26 | 31 | 41 | 44 | 49 | 52 |
| Borrowings | 7 | 9 | 11 | 31 | 36 | 37 | 33 | 30 | 34 | 31 | 26 | 28 | 28 |
| Other Liabilities | 9 | 10 | 8 | 12 | 26 | 12 | 16 | 17 | 18 | 27 | 18 | 26 | 23 |
| Total Liabilities | 21 | 24 | 32 | 70 | 101 | 84 | 83 | 87 | 104 | 120 | 108 | 123 | 124 |
| Fixed Assets | 5 | 6 | 6 | 47 | 47 | 47 | 50 | 48 | 45 | 50 | 60 | 54 | 52 |
| CWIP | 0 | 0 | 8 | 1 | 8 | 5 | 1 | 3 | 13 | 14 | 1 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 6 | 6 | 7 |
| Other Assets | 16 | 18 | 18 | 22 | 46 | 32 | 32 | 37 | 44 | 52 | 42 | 62 | 64 |
| Total Assets | 21 | 24 | 32 | 70 | 101 | 84 | 83 | 87 | 104 | 120 | 108 | 123 | 124 |
Below is a detailed analysis of the balance sheet data for Archit Organosys Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 23.00 Cr.. The value appears to be improving (decreasing). It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 123.00 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 54.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Investments, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 62.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears strong and on an upward trend. It has increased from 123.00 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 1.00 Cr..
Notably, the Reserves (52.00 Cr.) exceed the Borrowings (28.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -7.00 | -8.00 | -27.00 | -32.00 | -40.00 | -29.00 | -19.00 | -17.00 | -11.00 | -19.00 | -15.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 101 | 76 | 79 | 86 | 140 | 62 | 94 | 97 | 72 | 107 | 72 | 67 |
| Inventory Days | 10 | 28 | 28 | 27 | 41 | 30 | 22 | 21 | 22 | 16 | 16 | 18 |
| Days Payable | 80 | 72 | 63 | 80 | 126 | 55 | 88 | 87 | 51 | 110 | 62 | 94 |
| Cash Conversion Cycle | 31 | 33 | 44 | 33 | 56 | 38 | 28 | 30 | 44 | 13 | 26 | -8 |
| Working Capital Days | 8 | -1 | 3 | 19 | 12 | -23 | -39 | -15 | -0 | 10 | 10 | 45 |
| ROCE % | 19% | 20% | 17% | 9% | 6% | -4% | 3% | 12% | 18% | 17% | 4% | 11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.46 | 1.63 | 5.57 | 4.01 | 3.33 |
| Diluted EPS (Rs.) | 2.46 | 1.63 | 5.57 | 4.24 | 3.33 |
| Cash EPS (Rs.) | 5.36 | 4.38 | 7.92 | 6.29 | 5.77 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.72 | 31.26 | 30.14 | 25.29 | 26.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.72 | 31.26 | 30.14 | 25.29 | 26.99 |
| Dividend / Share (Rs.) | 0.50 | 0.00 | 0.50 | 0.75 | 0.50 |
| Revenue From Operations / Share (Rs.) | 61.21 | 55.16 | 62.27 | 66.60 | 62.92 |
| PBDIT / Share (Rs.) | 7.83 | 4.51 | 10.15 | 9.04 | 7.72 |
| PBIT / Share (Rs.) | 4.93 | 1.75 | 7.79 | 6.76 | 5.28 |
| PBT / Share (Rs.) | 3.67 | 2.14 | 7.52 | 5.57 | 3.12 |
| Net Profit / Share (Rs.) | 2.46 | 1.63 | 5.57 | 4.01 | 3.33 |
| PBDIT Margin (%) | 12.78 | 8.17 | 16.29 | 13.57 | 12.26 |
| PBIT Margin (%) | 8.05 | 3.17 | 12.51 | 10.14 | 8.38 |
| PBT Margin (%) | 6.00 | 3.87 | 12.07 | 8.36 | 4.95 |
| Net Profit Margin (%) | 4.02 | 2.94 | 8.94 | 6.02 | 5.29 |
| Return on Networth / Equity (%) | 7.29 | 5.20 | 18.47 | 15.86 | 12.35 |
| Return on Capital Employeed (%) | 13.10 | 4.85 | 20.41 | 21.02 | 14.90 |
| Return On Assets (%) | 4.10 | 3.08 | 9.33 | 7.94 | 5.72 |
| Long Term Debt / Equity (X) | 0.06 | 0.11 | 0.22 | 0.23 | 0.29 |
| Total Debt / Equity (X) | 0.38 | 0.40 | 0.50 | 0.61 | 0.53 |
| Asset Turnover Ratio (%) | 1.09 | 0.98 | 1.13 | 1.43 | 1.11 |
| Current Ratio (X) | 1.35 | 1.21 | 1.20 | 1.14 | 0.99 |
| Quick Ratio (X) | 1.25 | 1.11 | 1.13 | 0.98 | 0.89 |
| Inventory Turnover Ratio (X) | 32.43 | 10.10 | 8.42 | 11.41 | 8.98 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 30.73 | 13.46 | 12.46 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 11.40 | 9.46 | 7.94 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 69.27 | 86.54 | 87.54 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 88.60 | 90.54 | 92.06 | 0.00 |
| Interest Coverage Ratio (X) | 6.23 | 3.59 | 9.43 | 7.60 | 3.57 |
| Interest Coverage Ratio (Post Tax) (X) | 2.96 | 0.98 | 5.43 | 4.37 | 2.54 |
| Enterprise Value (Cr.) | 103.28 | 110.21 | 149.75 | 106.90 | 55.06 |
| EV / Net Operating Revenue (X) | 0.82 | 0.97 | 1.17 | 0.78 | 0.58 |
| EV / EBITDA (X) | 6.43 | 11.91 | 7.19 | 5.76 | 4.75 |
| MarketCap / Net Operating Revenue (X) | 0.61 | 0.78 | 0.96 | 0.58 | 0.39 |
| Retention Ratios (%) | 0.00 | 69.26 | 86.53 | 87.53 | 0.00 |
| Price / BV (X) | 1.11 | 1.38 | 2.00 | 1.54 | 0.91 |
| Price / Net Operating Revenue (X) | 0.61 | 0.78 | 0.96 | 0.58 | 0.39 |
| EarningsYield | 0.06 | 0.03 | 0.09 | 0.10 | 0.13 |
After reviewing the key financial ratios for Archit Organosys Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.36. This value is within the healthy range. It has increased from 4.38 (Mar 24) to 5.36, marking an increase of 0.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.72. It has increased from 31.26 (Mar 24) to 33.72, marking an increase of 2.46.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.72. It has increased from 31.26 (Mar 24) to 33.72, marking an increase of 2.46.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has increased from 0.00 (Mar 24) to 0.50, marking an increase of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.21. It has increased from 55.16 (Mar 24) to 61.21, marking an increase of 6.05.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 4.51 (Mar 24) to 7.83, marking an increase of 3.32.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.93. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 4.93, marking an increase of 3.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has increased from 2.14 (Mar 24) to 3.67, marking an increase of 1.53.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
- For PBDIT Margin (%), as of Mar 25, the value is 12.78. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 12.78, marking an increase of 4.61.
- For PBIT Margin (%), as of Mar 25, the value is 8.05. This value is below the healthy minimum of 10. It has increased from 3.17 (Mar 24) to 8.05, marking an increase of 4.88.
- For PBT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 3.87 (Mar 24) to 6.00, marking an increase of 2.13.
- For Net Profit Margin (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 5. It has increased from 2.94 (Mar 24) to 4.02, marking an increase of 1.08.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.29. This value is below the healthy minimum of 15. It has increased from 5.20 (Mar 24) to 7.29, marking an increase of 2.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.10. This value is within the healthy range. It has increased from 4.85 (Mar 24) to 13.10, marking an increase of 8.25.
- For Return On Assets (%), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has increased from 3.08 (Mar 24) to 4.10, marking an increase of 1.02.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.38, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has increased from 0.98 (Mar 24) to 1.09, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.35, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 1.25, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 32.43. This value exceeds the healthy maximum of 8. It has increased from 10.10 (Mar 24) to 32.43, marking an increase of 22.33.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 30.73 (Mar 24) to 0.00, marking a decrease of 30.73.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.40 (Mar 24) to 0.00, marking a decrease of 11.40.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 69.27 (Mar 24) to 0.00, marking a decrease of 69.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.60 (Mar 24) to 0.00, marking a decrease of 88.60.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.23. This value is within the healthy range. It has increased from 3.59 (Mar 24) to 6.23, marking an increase of 2.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.96. This value is below the healthy minimum of 3. It has increased from 0.98 (Mar 24) to 2.96, marking an increase of 1.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 103.28. It has decreased from 110.21 (Mar 24) to 103.28, marking a decrease of 6.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 24) to 0.82, marking a decrease of 0.15.
- For EV / EBITDA (X), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 6.43, marking a decrease of 5.48.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.61, marking a decrease of 0.17.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 69.26 (Mar 24) to 0.00, marking a decrease of 69.26.
- For Price / BV (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.38 (Mar 24) to 1.11, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.61, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Archit Organosys Ltd:
- Net Profit Margin: 4.02%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.1% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.29% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.96
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.9 (Industry average Stock P/E: 59.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.02%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | 9th Floor, Venus Benecia, Ahmedabad Gujarat 380054 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kandarp K Amin | Chairman & Wholetime Director |
| Mr. Archit K Amin | Whole Time Director |
| Mrs. Archana Amin | Whole Time Director |
| Mr. Nikul J Patel | Independent Director |
| Mr. Shreeraj V Desai | Independent Director |
| Mr. Bhavin G Shah | Independent Director |
| Mr. Vatsal S Vora | Independent Director |
FAQ
What is the intrinsic value of Archit Organosys Ltd?
Archit Organosys Ltd's intrinsic value (as of 16 January 2026) is ₹28.25 which is 31.76% lower the current market price of ₹41.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹85.0 Cr. market cap, FY2025-2026 high/low of ₹51.4/34.2, reserves of ₹52 Cr, and liabilities of ₹124 Cr.
What is the Market Cap of Archit Organosys Ltd?
The Market Cap of Archit Organosys Ltd is 85.0 Cr..
What is the current Stock Price of Archit Organosys Ltd as on 16 January 2026?
The current stock price of Archit Organosys Ltd as on 16 January 2026 is ₹41.4.
What is the High / Low of Archit Organosys Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Archit Organosys Ltd stocks is ₹51.4/34.2.
What is the Stock P/E of Archit Organosys Ltd?
The Stock P/E of Archit Organosys Ltd is 12.9.
What is the Book Value of Archit Organosys Ltd?
The Book Value of Archit Organosys Ltd is 35.5.
What is the Dividend Yield of Archit Organosys Ltd?
The Dividend Yield of Archit Organosys Ltd is 1.21 %.
What is the ROCE of Archit Organosys Ltd?
The ROCE of Archit Organosys Ltd is 10.8 %.
What is the ROE of Archit Organosys Ltd?
The ROE of Archit Organosys Ltd is 7.62 %.
What is the Face Value of Archit Organosys Ltd?
The Face Value of Archit Organosys Ltd is 10.0.